Everest Medicines Announces Positive Topline Results from Induction Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderate-to-Severe Active Ulcerative Colitis

[ad_1] –Clinically meaningful and statistically significant results demonstrated for primary endpoint and key secondary endpoints for the 12-week induction period– –Etrasimod was well-tolerated and its safety profile was consistent with…

Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

[ad_1] This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia…

Arvind SmartSpaces signs new residential apartment project in Bengaluru with top-line potential of Rs 400 crore – Industry News

[ad_1] Real estate development company Arvind SmartSpaces Limited (ASL), which is a part of the Lalbhai group, announced that it has signed a new residential apartment project in Bengaluru, with…

Manulife reports strong topline results in 2Q23 with APE sales up 12%, NBV up 10%, new business CSM of $592 million up 15% and Global Wealth and Asset Management net inflows of $2.2 billion. Net income attributed to shareholders was $1.0 billion in 2Q23 and core earnings were $1.6 billion with strong EPS and core EPS growth

[ad_1] C$ unless otherwise stated                                  TSX/NYSE/PSE: MFC               …

TopLine Named Finalist for Two Twin Cities Business 2023 “Best of Business” Reader’s Choice Awards

[ad_1] MAPLE GROVE, Minn., June 27, 2023 (GLOBE NEWSWIRE) — Local member-owned financial services cooperative TopLine Financial Credit Union has been named Twin Cities Business 2023 Best of Business Reader’s…

Movinn Q1 2023 – Interim Report: +27% topline growth, Sweden evolving as expected with bottom line metrics in Denmark below expectations | MarketScreener

[ad_1] Growth remain substantial and Movinn Sverige is close to B/E point. Demand in Denmark has been weaker than expected but we see improvement in Q2 and we maintain guidance…